News Releases

Date Title and Summary
Toggle Summary University of Bonn study shows that non-invasive vagus nerve stimulation (nVNS) device reduces number of migraine attacks and their intensity
A study published in the Journal of Headache and Pain, carried out by Dr. Thomas Kinfe of the University of Bonn, found that twice daily stimulation of the vagus nerve with the hand-held gammaCore nVNS device reduced the number of headache days per month from 14.7 to 8.9 (p
Toggle Summary Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
ROCKAWAY, N.J. , April 30, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of its most recent Truvaga Plus consumer study conducted earlier this year.
Toggle Summary TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project
ROCKAWAY, N.J. , June 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Performance product, has been selected to be a part of the Air
Toggle Summary Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning
Clinical trial (n=36) shows the ability of gammaCore (nVNS) to significantly improve the recall of a foreign language compared to sham while simultaneously showing improved focus and decreased fatigue in study participants ROCKAWAY, N.J. , April 24, 2023 (GLOBE NEWSWIRE) -- electroCore,
Toggle Summary Study of Non-Invasive Vagus Nerve Stimulation (nVNS) Shows Improvement in PTSD Symptoms and Decreased Inflammatory Response to Stress
ROCKAWAY, NJ , Aug. 10, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, “Transcutaneous Cervical Vagal Nerve Stimulation (tcVNS/nVNS) in Patients with Posttraumatic Stress
Toggle Summary Seven presentations on electroCore’s treatment for cluster headache and migraine will feature at American Headache Society science meeting.
Recent clinical and preclinical results using electroCore’s non-invasive vagus nerve stimulation (nVNS, gammaCore®) therapy in the treatment and prevention of primary headache are the subject of seven presentations at the American Headache Society (AHS) Science Meeting being held at San Diego next
Toggle Summary Reorganization of electroCore management team as Frank Amato becomes CEO and founder JP Errico becomes Chief Science and Strategy Officer.
Basking Ridge, New Jersey: Frank Amato, previously Chief Operating Officer, has been appointed Chief Executive Officer of electroCore, the Merck-backed world leader in non-invasive vagus nerve stimulation (nVNS) therapy. This change is part of a management-proposed development plan, unanimously
Toggle Summary Real-World Evidence and Insights into gammaCore™ (nVNS) Mechanism of Action to be Presented at the American Academy of Neurology’s 71st Annual Meeting
BASKING RIDGE, N.J. , May 03, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that two oral presentations featuring non-invasive vagus nerve stimulation (nVNS) will be presented at the 71 st Annual Meeting of the American
Toggle Summary Publicis Health CEO Joins electroCore’s Board of Directors
Nick Colucci Brings Invaluable Healthcare Communications Expertise to Enhance electroCore’s Continued Growth   Basking Ridge, NJ, August 29, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that
Toggle Summary Presentation shows that healthcare costs for patients with a primary headache diagnosis cost four times more than a healthy patient due to comorbidities
Research presented at the Academy of Managed Care Pharmacy (AMCP) Nexus in early October in Washington, DC, showed that 60 percent of adult patients who were diagnosed with primary headache had one or more comorbidities which raised the average annual cost of their healthcare to over $20,000.